Recent News

• 03.12.2025 - Amarin Corporation’s Fourth Quarter & Full Year 2024 Results
• 02.27.2025 - Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
• 02.27.2025 - Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
• 02.25.2025 - Amarin Receives National Reimbursement for VAZKEPA® in Austria
• 02.25.2025 - Amarin Receives National Reimbursement for VAZKEPA® in Austria
• 02.19.2025 - Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
• 02.19.2025 - Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
• 12.16.2024 - Amarin Receives National Reimbursement for VAZKEPA® in Italy
• 12.16.2024 - Amarin Receives National Reimbursement for VAZKEPA® in Italy
• 12.13.2024 - Amarin Appoints Peter Fishman Chief Financial Officer

Recent Filings

• 01.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.18.2024 - 8-K Current report
• 12.18.2024 - EX-99.1 EX-99.1